Press release, Helsinki, 25 th September 2018 at 9:00 AM EEST
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), the targeted neuromodulation company developing and marketing navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), announces that the Company will hold a conference call today, Tuesday 25th September 2018 to present its new corporate strategy.
The conference call will be hosted by Chief Executive Officer, Martin Jamieson, Chief Financial Officer, Mikko Karvinen and Vice President and General Manager, North America, Steve Beller.
Conference Call/ Webcast Details
Tuesday 25th September 2018 at 4:00 p.m. EEST (3:00 p.m. CEST / 9:00 a.m. EDT).
The dial-in numbers for the conference call are:
FI: +358 (0)9 7479 0361
SE: +46 (0)8 5664 2753
UK: +44 (0)330 336 9128
US: +1 929-477-0402
Confirmation Code: 8851156
Webcast
The presentation will also be webcast and can be accessed from the following web address:
https://nexstim.com/news-and-events/events/event/news/nexstim-conference-call-strategic-update/
Further information is available on the website www.nexstim.com or by contacting:
Nexstim
Martin Jamieson
Chairman and CEO
+44 771 516 3942
martin.jamieson@nexstim.com
Citigate Dewe Rogerson
David Dible/ Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
nexstim@citigatedewerogerson.com
About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company’s proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.
Nexstim’s NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.